{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 40,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a process-flow layout to describe clinical trial progression.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/28",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.94,
        "x": 0.03,
        "y": 0.185
      },
      "kind": "diagram",
      "text": "Initial interim analysis, Next step, Phase 2 part 2, Endpoints",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e03ffaa-f8b5-4ae7-a148-268de13cebf2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ≥ 18 years, ECOG performance status 0 or 1. AE, adverse event; BOR, best overall response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SAE, serious adverse event; TTR, time to response.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "192ba4b6-b24c-4bf8-8aaa-0fe6f3ca7829",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.75,
        "y": 0.37
      },
      "kind": "list",
      "text": "Primary endpoints: Confirmed ORR per RECIST v1.1, AEs or SAEs; Secondary endpoints: DOR, PFS, ORR, DCR, TTR, OS, tumor size",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8820197e-bb84-4518-ab55-b7698d367918",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.05,
        "y": 0.37
      },
      "kind": "list",
      "text": "ROR2+ ≥1 TmPS; Melanoma: PD1 failure; NSCLC: PD1, EGFR or ALK failure; SCCHN: PD1 alone or in combination w/ platinum failure; Monotherapy and Combination with PD-1/L1; Targeting up to ~20 pts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee2745bf-b966-4b55-bd27-9ed454e1e693",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.27,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "If definitive, move into part 2; Ability to continue enrollment up to ~40 patients, if desired",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bfc8ec6-8540-4783-a963-44c355021252",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.5,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "Monotherapy (BA3021) and / or Combination(BA3021+Opdivo); n=TBD pending discussions with FDA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5d44ff7-3b58-4599-983a-164cf2a20d28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.03,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "*To date, CR on first scan (3 doses), n=1",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a06f277-a155-42b4-bd69-5cd703380e3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 2 study design with BA3021 (Ozuriftamab Vedotin) in refractory patients for each indication: NSCLC, Melanoma, and SCCHN",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12be39b9-e902-480d-970f-a230288cd872",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}